Japan's R-zone likely to shrink in 1998
This article was originally published in Clinica
A reduction in the reasonable discounting rate for medical devices, or R-zone, will almost certainly be a primary objective of Japan's Ministry of Health and Welfare at the next major round of price revisions in April 1998. While prospects for market expansion in 1997 and 1998 continue to be positive, government plans to reform Japan's health insurance system and curb spending growth could have a negative impact on profitability, says the US Health Industry Manufacturers Association's Global Medical Technology Update.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.